Stock JNJB34 JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Johnson & Johnson Sao Paulo

Equities

JNJB34

BRJNJBBDR002

Market Closed - Sao Paulo
Other stock markets
 21:05:00 07/06/2024 BST 		5-day change 1st Jan Change
52.3 BRL +2.61% Intraday chart for Johnson & Johnson +1.75% +3.77%
06-08 Top law firms in US opioid lawsuits to get hundreds of millions in fees RE
06-07 J&J-backed Rapport Therapeutics shares debut nearly 6% higher RE

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JOHNSON & JOHNSON Stock Johnson & Johnson
+3.77% 354B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 632B
B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
A+
NOVARTIS AG Stock Novartis AG
+11.88% 216B
B-
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-0.73% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. JNJB34 Stock
  5. Ratings Johnson & Johnson
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW